Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPDO-1603 in moderate-to-severe Alzheimer's disease
NCT04229927Phase 3Unknown
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of donepezil, memantine in Alzheimer's disease (AD), sponsored by Hyundai Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
donepezilmemantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04229927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229927.